p73a Polyclonal Antibody | anti-p73a antibody

Anti - p73a

Cat. Num. AAA616349

• Reactivity: Human, Monkey
• Applications: ELISA, Western Blot
• Purity: Affinity purified over the control-peptide Sepharose
• Synonyms: p73a; Polyclonal Antibody; Anti - p73a; anti-p73a antibody

• Host: Host: Rabbit; Source: Human
• Reactivity: Human, Monkey
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Is 100% conserved in monkey, 86% in mouse and 54% in non-mammalian p73 from Barbus barbus. It has no significant homology with p53. Antibody crossreactivity in various species is not established. Control peptide, because of its low MW (<3kD), is not suitable for Western. It should be used for ELISA or antibody blocking to confirm antibody specificity
• Purity/Purification: Affinity purified over the control-peptide Sepharose
• Form/Format: Affinity Purified; Supplied as a liquid in PBS, pH 7.4, 0.1% BSA, 0.02% sodium merthiolate, 40% glycerol.
• Concentration: 1mg/ml (varies by lot)

• Applicable Applications for anti-p73a antibody: ELISA, Western Blot
• Application Notes: Suitable for use in ELISA, Western Blotting. Other applications not tested.; Dilution: Western Blot: 1:1000-1:5000 for neat serum and 1-10ug/ml for affinity pure using ECL.; ELISA: ~1:100,000 using 50-100ng control peptide/well.; Optimal dilutions to be determined by the researcher.
• Immunogen: A 22 amino acid peptide sequence mapping at the C-terminus of human p73a (1) was used to generate anti-human p73a. The peptide was coupled with KLH (carrier protein)
• Preparation and Storage: May be stored at 4 degree C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Product Categories/Family for anti-p73a antibody

Abs to Transcription Factors

References

• :1. Kaghad, M et al (1997) Cell 90, 809-819;
• 2. Oren, M (1997) Cell 90, 829-832; Herranz M et al (1999) Cancer Res. 59, 2068-2071; Yang A et al (2000) Nature 404, 99-103